Cysteine leukotrienes as key mediators of immune-dependent diseases and the therapeutic potential of the leukotriene receptor antagonist (montelukast). Part 1

Background. Cysteine leukotrienes are lipid mediators formed upon activation of the 5-lipoxygenase pathway of arachidonate metabolism. These are universal mediators with a wide spectrum of action, affecting almost all aspects of mammalian biology. In clinical allergy and immunology they are best kno...

Full description

Bibliographic Details
Published in:	Лечащий Врач
Main Authors:	N. G. Astafieva, I. E. Mikhailova, E. O. Gaisina, I. A. Perfilova, E. N. Udovichenko
Format:	Article
Language:	Russian
Published:	Open Systems Publication 2024-04-01
Subjects:	allergic rhinitis asthma phenotypes leukotrienes montelukast
Online Access:	https://journal.lvrach.ru/jour/article/view/1217

Similar Items

Cysteine leukotrienes as key mediators of immune-dependent diseases and the therapeutic potential of the leukotriene receptor antagonist (montelukast). Part 2
by: N. G. Astafieva, et al.
Published: (2024-05-01)

Anti-leukotriene agents in modern therapy of bronchial asthma in children
by: Yu. L. Mizernitskiy
Published: (2020-03-01)

Comparison of Leukotriene Receptor Antagonist and Antihistamine Therapy in Seasonal Allergic Rhinitis
by: Murat Yarıktaş, et al.
Published: (2002-12-01)

Leukotrienes vs. Montelukast—Activity, Metabolism, and Toxicity Hints for Repurposing
by: Cátia F. Marques, et al.
Published: (2022-08-01)

Non-obvious effects of montelukast – leukotriene receptor blocker: frigoprotective and anticonvulsant properties
by: S.Yu. Shtrygol, et al.
Published: (2021-06-01)

Effects of oral cysteine leukotriene receptor antagonist-montelukast on adenoid lymphoid tissue: a histopathological study under light microscope
by: Zhengying Wang, et al.
Published: (2023-11-01)

Effect of montelukast on leukotriene B4 metabolism in asthma
by: HU Yu, et al.
Published: (2023-05-01)

Leukotriene antagonists reduce epileptic seizures‐related hospitalization in older adult populations with allergic rhinitis or asthma: A population‐based cohort study using the Shizuoka Kokuho database: The Shizuoka study
by: Yutaro Imaichi, et al.
Published: (2024-02-01)

Leukotriene Receptor Antagonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-analysis
by: Safa Fawaza Mahmood, et al.
Published: (2025-05-01)

Comparative Study to Assess Clinical Efficacy of Leukotriene Receptor Antagonist and Antihistamines in the Treatment of Allergic Rhinitis
by: Gurpreet Kaur, et al.
Published: (2017-08-01)

Comparative Study to Assess Clinical Efficacy of Leukotriene Receptor Antagonist and Antihistamines in the Treatment of Allergic Rhinitis
by: Gurpreet Kaur, et al.
Published: (2017-08-01)

Pediatric Asthma: Where Has Montelukast Gone?
by: Marco Maglione, et al.
Published: (2023-03-01)

Montelukast: risk of mental disorders vs. efficacy–a meta-analysis
by: Marharyta Sobczak, et al.
Published: (2025-10-01)

Evaluating the safety and efficacy of the leukotriene receptor antagonist montelukast as adjuvant therapy in obese patients with type 2 diabetes mellitus: A double-blind, randomized, placebo-controlled trial
by: Eman El-Khateeb, et al.
Published: (2023-04-01)

The Efficacy of Montelukast Monotherapy in Moderate Persistent Asthmatic Children
by: Mahir Igde, et al.
Published: (2009-09-01)

Theophylline and leukotriene modifiers: Is there any compelling role in COPD?
by: Abhijeet Singh, et al.
Published: (2020-01-01)

Montelukast As An Add On Therapy In Asthma As Compared To Its Use In Asthma Associated With Concomitant Rhinitis Symptoms
by: kassim M. Sultan
Published: (2011-07-01)

Evaluation of Neuropsychiatric Effects of Montelukast–Levocetirizine Combination Therapy in Children with Asthma and Allergic Rhinitis
by: Uğur Altaş, et al.
Published: (2023-07-01)

Meta-analysis of the relationship between montelukast use and neuropsychiatric events in patients with allergic airway disease
by: Yakui Mou, et al.
Published: (2023-11-01)

Leukotriene Signaling as a Target in α-Synucleinopathies
by: Katharina Strempfl, et al.
Published: (2022-02-01)

Comparison of therapeutic efficacy of antihistaminics and combinations of montelukast with allergic rhinitis
by: Erkan Yildiz, et al.
Published: (2019-12-01)

Potential of Anti-Leukotriene Drugs as New Therapeutic Agents for Inhibiting Cholangiocarcinoma Progression
by: Yusuke Kito, et al.
Published: (2024-07-01)

Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma
by: Scaparrotta Alessandra, et al.
Published: (2012-07-01)

Montelukast Influence on Lung in Experimental Diabetes
by: Cristina Gales, et al.
Published: (2024-04-01)

Expression of cysteinyl leukotriene receptor 1 in adenoid tissue of children with adenoid hypertrophy and its influencing factors
by: ZHANG Bing, GUAN Renzheng, JIN Rong, LIN Rongjun, WANG Xuehai
Published: (2024-06-01)

BRONCHIAL OBSTRUCTION IN CHILDREN: A NEW SOLUTION TO AN OLD PROBLEM
by: O. I. Simonova, et al.
Published: (2015-04-01)

Promising Effects of Montelukast for Critically Ill Asthma Patients via a Reduction in Delirium
by: Yuan Li, et al.
Published: (2024-01-01)

Increased Risk of Tourette Syndrome with Leukotriene Modifier Use in Children with Allergic Diseases and Asthma: A Nationwide Population-Based Study
by: Min-Lan Tsai, et al.
Published: (2022-10-01)

Effect of a leukotriene receptor antagonist pranlukast hydrate, on airway inflammation airway hyperresponsiveness in patients with moderate to severe asthma
by: Kiyoko Wada, et al.
Published: (2000-01-01)

Montelukast and Acute Coronary Syndrome: The Endowed Drug
by: Basil Mohammed Alomair, et al.
Published: (2022-09-01)

Leukotriene mechanisms of allergic enterocolitis pathogenesis in young children
by: O. H. Shadrin, et al.
Published: (2018-12-01)

Opportunities for correction of individual links of the pathogenesis of allergic rhinitis and bronchial asthma with assessment of the quality of life of patients
by: M. Yu. Korkmazov, et al.
Published: (2022-04-01)

A systematic review and meta-analysis of loratadine combined with montelukast for the treatment of allergic rhinitis
by: Huan Wang, et al.
Published: (2023-10-01)

New options in the treatment of allergic rhinitis
by: S. V. Ryazantsev, et al.
Published: (2015-12-01)

Suspected Adverse Drug Reactions Associated with Leukotriene Receptor Antagonists Versus First-Line Asthma Medications: A National Registry–Pharmacology Approach
by: Mohammed Khan, et al.
Published: (2025-09-01)

Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial
by: Morteza Pourahmad, et al.
Published: (2024-06-01)

Role of montelukast in asthma treatment in 2025
by: Rafał Pawliczak
Published: (2025-02-01)

Comparison of treatment efficacy of omega-3 fish oil and montelukast in ovalbumin-protease-induced allergic rhinitis model in rats
by: Alper Tabaru, et al.
Published: (2024-05-01)

Comparison of the effect of desloratadine and montelukast combined treatment with desloratadine monotherapy on clinical symptoms and quality of life of patients with persistent allergic rhinitis
by: Meghdad Rahati, et al.
Published: (2023-12-01)

Anti-leukotriene compared to inhaled corticosteroid for recurrent wheezing in children under five years of age: A randomized clinical trial
by: Mahnaz Sadeghi-Shabestari, et al.
Published: (2024-12-01)